Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Supply of Anapeine Generic to Start by Year-End: Minister
October 9, 2024
- MHLW Issues Notification to Spur Use of RWD in Place of Clinical Trial Data
October 7, 2024
- New Health Minister to Stick to Honebuto Text on Off-Year Plan
October 7, 2024
- Ishiba Makes No Mention on Pharma in First Policy Speech
October 7, 2024
- Komeito’s Yoko Wanibuchi Newly Named Senior Vice Health Minister
October 4, 2024
- Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment
October 4, 2024
- New Health Minister Eager to Build Pharma Ecosystem in Japan
October 3, 2024
- AMED to Assign Staff by Seed to Ensure End-to-End Support from FY2025
October 3, 2024
- New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision
October 3, 2024
- MHLW Plans to Ease Rules on Public Knowledge-Based Applications during Re-Examination Period
October 3, 2024
- New Cabinet Might Move the Needle in Off-Year Debate: Industry Exec
October 2, 2024
- Japan’s New PM Eyes Social Security Reform as Cabinet Unveiled
October 2, 2024
- MHLW Council Endorses Early Approval Scheme for Medical Countermeasures
October 2, 2024
- Takamaro Fukuoka Named as New Health Minister
October 1, 2024
- Japan Compiles First Biosimilar Roadmap
October 1, 2024
- Japan Sets Up “Moderate-Risk” Post-Approval Change for Shorter Review
October 1, 2024
- Ex-Health Minister Nemoto to Retire from Politics
October 1, 2024
- Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies
September 30, 2024
- MHLW Set to Redefine “Vaccines of High Development Priority” in New Plan
September 27, 2024
- MHLW to Publish Info Necessary for Driving Biosimilar Switches in FY2025
September 27, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…